

\$1642
BOX 500



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

MAR -4 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Docket No.: 186.009US1

Serial No.: 09/637,530

Filed: August 11, 2000

Due Date: February 6, 2002

Examiner: Stephen L. Rawlings

Group Art Unit: 1642

Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Communication Under 37 CFR 1.821 (1 page).
- ☒ Sequence Listing (4 pgs.).
- ☒ ASCII Computer-Readable Sequence Listing (1 disk).
- ☒ Copy of Notice To Comply (from Paper No. 7) (1 page).
- ☒ Petition for one-month extension of time, with authorization to charge fee to Deposit Acct. 19-0743.

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Ann M. McCrackin
Atty: Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 1 day of February, 2002.

Candis B. Buending

Name


Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

S/N 09/637,530



COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Examiner: Stephen L. Rawlings

Serial No.: 09/637,530

Group Art Unit: 1642

Filed: August 11, 2000

Docket: 186.009US1

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

8
3/15/02

COMMUNICATION UNDER 37 CFR § 1.821

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

MAR -4 2002
TECH CENTER 1600/2900

Sir:

In response to the Office communication mailed December 6, 2001 (Paper No. 7), a SEQUENCE LISTING is submitted herewith, along with a copy of the Notice to Comply, as requested.

In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith.

It is respectfully submitted that the contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same.

It is further submitted that the paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not represent new matter.

Respectfully submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 349-9592

Date Feb. 1, 2002

By Ann M. McCrackin

Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 1 day of February, 2002.

Candis B. Buending

Name

Signature

Candis B. Buending

MAR - 4 2002

Notice to Comply

Application No.

09/637,530

Examiner

Stephen I. Rawlings, Ph.D.

Applicant(s)

STANNERS ET AL

Art Unit

1642

TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY